Nature Reviews Drug Discovery contents June 2015 Volume 14 Number 6 pp 367-444

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
June 2015 Volume 14 Number 6		Advertisement
Impact Factor 37.231 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Correspondence Also this month  Featured article: Malaria medicines: a glass half full? Timothy N. C. Wells, Rob Hooft van Huijsduijnen & Wesley C. Van Voorhis	MonoExpress™ Application-Guaranteed mAb Production Services We guarantee at least one clone will work for your application.  Get details HERE
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
Presented by Adaptive Biotechnologies, Nature Immunology, Nature Medicine, Nature Biotechnology, and Nature Genetics IMMUNE PROFILING IN HEALTH AND DISEASE September 9-11, 2015 | Seattle, WA, USA REGISTER NOW!
Comment: Drug development for airway diseases: looking forward Stephen Holgate, Alvar Agusti, Robert M. Strieter, Gary P. Anderson, Robert Fogel, Elisabeth Bel, Thomas R. Martin & Theodore F. Reiss p367 | doi:10.1038/nrd4645 Advancing drug development for airway diseases beyond the established mechanisms and symptomatic therapies requires redefining the classifications of airway diseases, considering systemic manifestations, developing new tools and encouraging collaborations. Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
Oncolytic viruses get a boost with first FDA-approval recommendation Elie Dolgin p369 | doi:10.1038/nrd4643 The future of cancer-killing viruses lies in their potential to augment cell and antibody immunotherapies. PDF
Regulators and industry tackle dose-finding issues Asher Mullard p371 | doi:10.1038/nrd4644 Industry experts ask for regulatory guidelines and assurance on the value of well-designed Phase IIb dose-finding studies to help overcome long-standing resistance to sophisticated dose-finding strategies. PDF
NEWS IN BRIEF Immunotherapy interest drives IDO deals Asher Mullard p373 | doi:10.1038/nrd4658 PDF
Cancer market hits $100 billion Asher Mullard p373 | doi:10.1038/nrd4659 PDF
GSK scores first Phase III shingles trial success Asher Mullard p373 | doi:10.1038/nrd4660 PDF
BIOBUSINESS BRIEFS Trial watch: Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy Megan Cully p374 | doi:10.1038/nrd4648 PDF
BIOBUSINESS BRIEFS Deal watch: Panning for gold: sourcing pharmaceutical innovation Myoung Cha, Abhishek Saxena, Katarzyna Smietana & Roerich Bansal p376 | doi:10.1038/nrd4647 PDF
AN AUDIENCE WITH Stéphane Bancel p378 | doi:10.1038/nrd4646 Stéphane Bancel, Chief Executive Officer of Moderna, discusses the opportunity and scientific overhangs of mRNA therapeutics. PDF
FROM THE ANALYST'S COUCH The chronic lymphocytic leukaemia market Mine Esencay & Bashar Hamad p381 | doi:10.1038/nrd4625 The market for drugs to treat chronic lymphocytic leukaemia has changed substantially recently with the introduction of novel targeted therapies. This article discusses the treatment landscape and highlights agents in the late-stage pipeline. PDF
RESEARCH HIGHLIGHTS Top Neurodegenerative diseases: Repurposing for remyelination p383 | doi:10.1038/nrd4641 PDF Respiratory diseases: Breathing easy with calcilytics p384 | doi:10.1038/nrd4639 PDF Antiviral drugs: Searching the store cupboard for low-cost HCV drugs p384 | doi:10.1038/nrd4640 PDF Viral infections: New options to fight Ebola p385 | doi:10.1038/nrd4642 PDF Neurodegenerative disease: Phosphatase inhibitor prevents protein-misfolding diseases p386 | doi:10.1038/nrd4638 PDF IN BRIEF Neurodegenerative disorders: New Huntington disease target identified | Cancer: Towards a personalized cancer vaccine | Heart disease: Stimulating cardiomyocyte regeneration after heart failure PDF Drug Discovery JOBS of the week Cheminformatics Programmer positions in the Center for Drug Discovery Baylor College of Medicine (BCM) Research Laboratory Head / Drug Discovery in Cancer Immunotherapy (m / f) Boehringer Ingelheim Postdoc in albumin-based drug delivery Aarhus University Postdoctoral Fellow Weill Cornell College of Medicine Research Fellow Mayo Medical School - Mayo Clinic More Science jobs from Drug Discovery EVENT Event Title Phenotypic and Biomarker-Based Drug Discovery 27.10.15 New York, USA More science events from
PERSPECTIVES		Top
OPINION Predicting drug metabolism: experiment and/or computation? Johannes Kirchmair, Andreas H. Göller, Dieter Lang, Jens Kunze, Bernard Testa, Ian D. Wilson, Robert C. Glen & Gisbert Schneider p387 | doi:10.1038/nrd4581 Efficient and reliable ways to predict drug metabolism early in the drug discovery process are important in reducing the risk of costly later-stage attrition. Schneider and colleagues summarize the state of the art in experimental and computational approaches for investigating drug metabolism, and discuss strategies to harness the potential synergies between them. Abstract | Full Text | PDF
REVIEWS		Top
Exploiting replicative stress to treat cancer Matthias Dobbelstein & Claus Storgaard Sorensen p405 | doi:10.1038/nrd4553 Inhibiting the progression of rapidly dividing cancer cells through the cell cycle has long been pursued as an anticancer strategy. Dobbelstein and Sorensen discuss an alternative approach based on exploiting inherent defects in the DNA replication machinery in cancer cells to promote replicative stress and cell death, and discuss how agents that increase replicative stress might be useful either alone or in combination with conventional chemotherapeutics. Abstract | Full Text | PDF
Malaria medicines: a glass half full? Timothy N. C. Wells, Rob Hooft van Huijsduijnen & Wesley C. Van Voorhis p424 | doi:10.1038/nrd4573 Despite considerable advances in malaria medicines in the past 20 years, the global burden of malaria remains substantial. Moreover, continued emergence of drug resistance ensures that new antimalarials will be needed in the near future. Wells and colleagues summarize the current landscape of antimalarial therapies and investigational drugs, highlighting the progress made, identifying gaps in terms of target profiles and recommending priorities for future research. Abstract | Full Text | PDF
CORRESPONDENCE		Top
Correspondence: Drug discovery for the developing world: progress at the Novartis Institute for Tropical Diseases Catherine L. Jones, Bryan K. S. Yeung, Ujjini Manjunatha, Pei-Yong Shi, Christophe Bodenreider & Thierry T. Diagana p442 | doi:10.1038/nrd4001-c1 Full Text | PDF
Advertisement
Celebrating the 25th Anniversary of SELEX: An Aptamer Symposium Supported by the American Society of Gene & Cell Therapy, the Aptamers Workshop will provide a unique opportunity to celebrate the 25th anniversary of aptamers and to meet researchers around the world developing nucleic acid aptamers as high affinity targeting reagents for both diagnosis and therapy. Find out more: www.asgct.org/am15/
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2015 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.